No abstract available.
Drug Therapy* ; Dyslipidemias*

No abstract available.
Drug Therapy* ; Dyslipidemias*

Dyslipidemia is very common in nephrotic syndrome, but in clinical practice this problem is not much interested in, although hyperlipidemia can make dangerous complications for the patients. This study examined the variety of dyslipidemia after steroid treatment in patients with nephrotic syndrome but without renal failure. We studied on 40 patients with nephrotic syndrome at HuÕ Central Hospital and found that before treatment, total cholesterol and LDL concentrations are high. After two-week therapy, these concentrations decreased but insignificantly. After four-week therapy, total cholesterol and LDL concentrations decreased, HDL concentration increased. There was significant difference in comparison with the pre-treated concentrations (p<0.05).
Nephrotic Syndrome ; Dyslipidemias ; therapy

Background: Dyslipidemia is an important risk factor of atherosclerosis. The endothelia can be injured by plaque that advantages for platelet adheadsion, aggregation and produces thrombosis. Objectives: (1) To evaluate the changes of platelet aggregation induced by ADP and collagen in hyperlipidemic patients; (2) To identify the relationship between platelet aggregation and various types of dyslipidemia. Subjects and methods: A descriptive cross sectional non-randomised control trial method was employed in this study. A total of 128 hyperlipidemic patients (in which 40 patients were type IIa, 36 were type lib, and 52 were type IV), and a control group of 88 people were measured the aggregation in platelet - rich plasma (PRP) induced by ADP and collagen. Results: There was no significant difference about the platelet counts in both intervention and control groups (p>0.05). ADP and collagen induced platelet aggregation increased significantly (p<0.01) in intervention group when compared to control group. A significant correlation was found between the plasma triglyceride concentration and platelet aggregation induced by ADP and collagen with r = 0,335 and 0,332 respectively, while that of cholesterol and ADP was 0,304. Conclusion: Platelet aggregation increased in hyperlipidemic patients and had a significant correlation with plasma triglyceride concentration. \r\n', u'\r\n', u'
Dyslipidemias/ pathology ; therapy ; Platelet Aggregation

Blood Pressure ; China/epidemiology* ; Consensus ; Dyslipidemias/therapy* ; Humans ; Hypertension/therapy*

Adolescent ; Child ; Dyslipidemias ; diagnosis ; therapy ; Guidelines as Topic ; Humans

To analyze the compatibility regularity of compound traditional Chinese medicine (TCM) patents for treating dyslipidemia, and provide basis for the clinical development and research of new TCM for treating dyslipidemia. Totally 243 compound traditional Chinese medicine patents for treating dyslipidemia were collected from the national patent database from September 1985 to March 2014 and analyzed by using drug frequency, association rules, complex network and entropy method of Traditional Chinese Medicine Inheritance System (V1.1). The commonest single medicine in the treatment of dyslipidemia is Crataegi Fructus 109 (44.86%). The commonest pair medicine is Crataegi Fructus-Salviae Miltiorrhizae Radix et Rhizoma 53 (21.81%). The commonest corner drug is Crataegi Fructus-Cassiae Semen-Polygoni Multiflori Radix 25 (10.29%). The common prescriptions on basis of association rules are Prunellae Spica-->Salviae Miltiorrhizae Radix et Rhizoma (0.833), Rhei Radix et Rhizoma, Alismatis Rhizoma-->Polygoni Multiflori Radix (1.00), Salviae Miltiorrhizae Radix et Rhizoma, Cassiae Semen, Alismatis Rhizoma-->Polygoni Multiflori Radix (0.929). The core drugs based on complex networks are Salviae Miltiorrhizae Radix et Rhizoma and Crataegi Fructus. The new prescriptions extracted by entropy method are Atractylodis Macrocephalae Rhizoma-Glycyrrhizae Radix et Rhizoma-Platycladi Semen-Stephaniae Tetrandrae Radix; Citri Reticulatae Pericarpium-Poria-Coicis Semen-Pinelliae Rhizoma. This study shows the regularity in the compatibility of compound TCM patents treating dyslipidemia, suggesting that future studies on new traditional Chinese medicines treating dyslipidemia should focus on the following six aspects: (1) Single medicine should be preferred: e. g. Crataegi Fructus; (2) Pair medicines should be preferred: e. g. Crataegi Fructus-Salviae Miltiorrhizae Radix et Rhizoma; (3) Corner drugs should be preferred: e. g. Crataegi Fructus, Cassiae Semen, Polygoni Multiflori Radix; (4) The compatibility among drugs shall be given attention, and highly correlated drugs should be preferred: e. g. Prunellae Spica, Salviae Miltiorrhizae Radix et Rhizoma; Rhei Radix et Rhizoma, Alismatis Rhizoma, Polygoni Multiflori Radix; Salviae Miltiorrhizae Radix et Rhizoma, Cassiae Semen, Alismatis Rhizoma, Polygoni Multiflori Radix; (5) Core drugs should be dominant and compatible, e. g. in the digestion catharsis method, the core drugs is Crataegi Fructus and compatible with Salviae Miltiorrhizae Radix et Rhizoma; (6) Application of new prescriptions: Atractylodis Macrocephalae Rhizoma, Glycyrrhizae Radix et Rhizoma, Platycladi Semen, Stephaniae Tetrandrae Radix; Citri Reticulatae Pericarpium, Poria, Coicis Semen, Pinelliae Rhizoma.
Dyslipidemias ; drug therapy ; Entropy ; Humans ; Medicine, Chinese Traditional ; Patents as Topic

Humans ; Dyslipidemias ; HIV Infections/drug therapy* ; Risk Factors

Animals ; Dyslipidemias ; embryology ; physiopathology ; Humans ; Renal Insufficiency, Chronic ; epidemiology ; physiopathology ; therapy ; Renal Replacement Therapy

The prevalence of dyslipidemia is increased in postmenopausal women due to dysregulation of lipid metabolism and deficiency of estrogen levels. At the same time, some postmenopausal women also have menopausal syndromes such as vasomotor symptoms, physical physiology, mental psychology, and urogenital tract atrophy. Menopausal hormone therapy is the most effective measure to alleviate menopausal syndrome. And initiating MHT in early menopause can reduce cardiovascular damage. However, menopausal hormone therapy can also bring the risk of thromboembolic diseases such as venous embolism, myocardial infarction and stroke. Different drug regimens have different effects on lipid metabolism. Women with menopausal syndrome should take individualized treatment plans for different types of dyslipidemia. Therefore, this article reviews the management and treatment of menopausal syndrome in women with dyslipidemia, so as to provide a reference for personalized management of dyslipidemia in postmenopausal women.
Female ; Humans ; Menopause ; Estrogen Replacement Therapy ; Cardiovascular Diseases/epidemiology* ; Estrogens/pharmacology* ; Dyslipidemias/drug therapy*